• Benchaoui, H.A., Siedek, E.M., De la Puente-Redondo, V.A., Tilt, N., Rowan, T.G. & Clemence, R.G. (2007) Confirmation of the efficacy of maropitant for the prevention of emesis associated with motion sickness in dogs presenting as clinical patients. The Veterinary Record, in press.
  • Bergman, A.J., Marbury, T., Fosbinder, T., Swan, S., Hickey, L., Bradstreet, T.E., Busillo, J., Petty, K.J., Aiyer, J.V., Constanzer, M., Huskey, S.W. & Majumdar, A. (2005) Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clinical Pharmacokinetics, 44, 637647.
  • Bergstrom, M., Hargreaves, R.J., Burns, H.D., Goldberg, M.R., Scibberas, D., Reines, S.A., Petty, K.J., Ogren, M., Antoni, G., Langstrom, B., Eskola, O., Scheinin, M., Solin, O., Majumdar, A.K., Constanzer, M.L., Battisti, W.P., Bradstreet, T.E., Gargano, C. & Hietala, J. (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biological Psychiatry, 55, 10071012.
  • De la Puente-Redondo, V., Clemence, R.G. & Ramsey, D.S. (2006) Maropitant (CERENIATM) Provides Robust Preventative and Therapeutic Antiemetic Efficacy in Dogs from 30 Minutes to 24 Hours after a Single Dose. Proceedings of the European College of Veterinary Internal Medicine, ECVIM, Amsterdam, The Netherlands.
  • De la Puente-Redondo, V., Siedek, E.M., Benchaoui, H.A., Tilt, N., Rowan, T.G. & Clemence, R.G. (2007a) The anti-emetic efficacy of maropitant (CereniaTM) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. Journal of Small Animal Practice, 48, 9398.
  • De la Puente-Redondo, V., Tilt, N., Rowan, T.G. & Clemence, R.G. (2007b) Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. American Journal of Veterinary Research, 68, 4856.
  • Diemunsch, P. & Grélot, L. (2000) Potential of substance P antagonists as antiemetics. Drugs, 60, 533546.
  • Hellriegel, E.T., Bjornsson, T.D. & Hauck, W.W. (1996) Interpatient variability in bioavailability is related to the extent of absorption: implication for bioavailability and bioequivalence studies. Clinical Pharmacology and Therapeutics, 60, 601607.
  • Hietala, J., Nyman, M.J., Eskola, O., Laakso, A., Gronroos, T., Oikonen, V., Bergman, J., Haaparanta, M., Forsback, S., Marjamaki, P., Lehikoinen, P., Goldberg, M., Burns, D., Hamill, T., Eng, W.S., Coimbra, A., Hargreaves, R. & Solin, O. (2005) Visualization and quantification of neurokinine-1 (NK1) receptors in the human brain. Molecular Imaging and Biology, 7, 262272.
  • Majumdar, A.K., Howard, L., Goldberg, M.R., Hickey, L., Constanzer, M., Rothenberg, P.L., Crumley, T.M., Panebianco, D., Bradstreet, T.E., Bergman, A.J., Waldman, S.A., Greenberg, H.E., Butler, K., Knops, A., De Lepeleire, I., Michiels, N. & Petty, K.J. (2006) Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. Journal of Clinical Pharmacology, 46, 291300.
  • OECD (1998) Principles of Good Laboratory Practice (as revised in 1997). Environmental Directorate, Organisation for Economic Co-operation and Development, Paris. Series on Principles of Good Laboratory Practice and Compliance Monitoring No. 1. OECD Environmental Health and Safety Publications, ENV/MC/CHEM(98)17, Paris.
  • Patel, L. & Lindley, C. (2003) Aprepitant-a novel NK1-receptor antagonist. Expert Opinion on Pharmacotherapy, 4, 22792296.
  • Reed-Hagen, A.E., Tsuchiya, M., Shimada, K., Wentland, J.-A. & Obach, R.S. (1999) Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites. Biopharmaceutics and Drug Disposition, 20, 429439.
  • Smith, B.J., Doran, A.C., McLean, S., Tingley, F.D., O'Neill, B.T. & Kajiji, S.M. (2001) P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. Journal of Pharmacology and Experimental Therapeutics, 298, 12521259.
  • Toutain, P.L. & Bousquet-Mélou, A. (2004a) Bioavailability and its assessment. Journal of Veterinary Pharmacology and Therapeutics, 27, 455466.
  • Toutain, P.L. & Bousquet-Mélou, A. (2004b) Plasma clearance. Journal of Veterinary Pharmacology and Therapeutics, 27, 415425.
  • VICH (GCP) (2000) International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products. Good Clinical Practice, Brussels, June 2000, effective 01 July 2001.